Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Salvage Treatment with Intermediate-Dose Methotrexate and 5-Fluorouracil in Metastatic Breast Cancer

Swain, S. M., M.D.; Steinberg, S., Ph.D.; Lippman, M., M.D.

American Journal of Clinical Oncology: August 1988 - Volume 11 - Issue 4 - p 445–447
Article: PDF Only

Twenty-six patients (25 evaluable for response) with previously treated metastatic breast cancer were treated with intermediate-dose methotrexate (300 mg/m2) followed by 5-fluorouracil (600 mg/m2) and folinic acid-SF (Leucovorin) rescue (10 mg/m2 q 6 h × 6 doses) with or without tamoxifen (20 mg) and conjugated estrogen (Premarin) (.625 mg twice daily) depending on receptor status. There were two partial responses (8%) with no difference in response between patients who did or did not receive hormones. Toxicity was primarily hematological and elevation of liver function tests. The above schedule has minimal activity in previously treated metastatic breast-cancer patients.

Medicine Branch (S.M.S, M.L.) and the Biostatistics and Data Management Section (S.S), Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland.

© Lippincott-Raven Publishers.